Skip to content

Price / book at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
+1.4×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
3.5×+0.3×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
1.8×+0.6×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
125.1×+108×
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
5.3×-0.8×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
316.5×+303×

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.58B+128%

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0.0×
Current ratio3.8×+0.1×

Where this comes from

Calculated from Kiniksa Pharmaceuticals International, plc’s reported figures.

Based on the most recent quarter.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's price / book?
Kiniksa Pharmaceuticals International, plc (KNSA) reported price / book of 6.1× in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's price / book changed year-over-year?
Kiniksa Pharmaceuticals International, plc's price / book increased by 72.5% year-over-year, from 3.5× to 6.1×.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's price / book?
Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's price / book has grown at a 7.1% compound annual growth rate (CAGR), from 3.9× to 5.5×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.